Research programme: trophic factor biotherapeutics - Mesoblast

Drug Profile

Research programme: trophic factor biotherapeutics - Mesoblast

Alternative Names: Cytokine biotherapeutics - Mesoblast; SDF-1 - Mesoblast; Stromal derived factor-1 - Mesoblast

Latest Information Update: 05 Feb 2014

Price : $50

At a glance

  • Originator Mesoblast
  • Class CXC chemokines; Peptides; Small molecules
  • Mechanism of Action Angiogenesis inducing agents; CXCR4 receptor agonists; Leukocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 29 Jan 2014 Preclinical trials in Cardiovascular disorders in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top